Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Eisai, Inc. and Exelixis, Inc.

Community Practice Connections™: Show Me the Data: The Experts Weigh-In on Evidence to Support Strategies for Classic Clinical Scenarios in Renal Cell Carcinoma

Release Date: August 31, 2017
Expiration Date: August 31, 2018
Media: Internet - based

 

Activity Overview

Community Practice Connections™: Show Me the Data: The Experts Weigh-In on Evidence to Support Strategies for Classic Clinical Scenarios in Renal Cell Carcinoma features case-based discussions about standard and emerging therapies for renal cell carcinoma (RCC). Interactive clinical vignettes are followed by brief video interviews with leading experts and short summaries of related clinical data. The vignettes and video interviews broach a variety of clinical scenarios at key junctures in care, with the understanding that real-world scenarios cannot always be bucketed neatly into simple “lines of therapy.” The format of this activity enables participants to reflect on how they arrive at the decisions they make, how their decisions compare with those of the faculty, whether they have a deep understanding of landmark trial results, and how to better contextualize evidence to optimize decision making at key decision points along the RCC treatment continuum.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Eisai, Inc. and Exelixis, Inc.

CME/CE Activity Table of Contents

  • Decision Point 1: What Goes Into Your Thought Processes for the Frontline Treatment of Advanced RCC?
    Daniel George, MD and Toni Choueiri, MD
  • Decision Point 2: What Goes Into Your Thought Process to Determine What Treatment to Select in the 2nd-Line Setting?
    Thomas E. Hutson, DO, PharmD and Toni Choueiri, MD
  • Decision Point 3: What Are the Options for Your Patient Who Has Non-Clear Cell RCC?
    Nizar M. Tannir, MD, FACP and Toni Choueiri, MD
  • Decision Point 4: Adjuvant Considerations Now and How Might They Change in the Near Future?
    Lauren C. Harshman, MD and Toni Choueiri, MD
  • Decision Point 5: How Can I Personalize Care for My Patients with RCC Biomarker?
    Thomas Powles, MBBS, MRCP, MD and Toni Choueiri, MD

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a cme/ce certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a cme/ce certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of renal cell carcinoma. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with renal cell carcinoma are invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Substantiate your treatment decisions in the management of advanced RCC at key decision points along the disease continuum based on the most relevant clinical trial evidence
  • Integrate knowledge of single-agent and combination strategies in the context of mechanisms of action, kinetics of response, best practices in monitoring, and key information that informs switching decisions in the care of patients with advanced RCC
  • Manage treatment-related toxicities and practically apply knowledge of adverse events as a component of monitoring and therapeutic decision making in RCC treatment settings
  • Assess recent clinical trial results, key ongoing trials that are highly anticipated in the field, and how emerging strategies may further impact the RCC treatment landscape

Faculty, Staff, and Planners' Disclosures

Faculty

Toni K. Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, MA
 

Disclosure: Grants/Research Support: Pfizer, GlaxoSmithKline, Novartis, Bristol-Myers Squibb, Merck, Exelixis, Roche, AstraZeneca, Tracon, Peloton, and Celldex; Consultant: Pfizer, GlaxoSmithKline, Novartis, Bayer, Eisai, Bristol-Myers Squibb, Merck, Roche, and Prometheus Laboratories Inc.

Daniel George, MD
Professor of Medicine
Professor in Surgery
Member of the Duke Cancer Institute
Department of Medicine
Duke University School of Medicine
Durham, NC

Disclosure: Grants/Research Support: Acerta Pharma, LLC, Exelixis, Janssen Pharmaceutical, Millennium Pharmaceuticals, Novartis, Pfizer, and Innocrin/Viamet Pharmaceuticals, Inc.; Consultant: Astellas Pharma, Bayer, Bristol-Myers Squibb, Clovis Oncology, Dendreon, Exelixis, Genentech, Innocrin, Medivation, Merck & Co., Myovant Science, Ltd. Novartis, Pfizer, and Sanofi; Member of Speakers Bureau: Bayer, Sanofi, Novartis, and Dendreon.

Lauren C. Harshman, MD
Co-Director, Kidney Cancer Program
Dana-Farber Cancer Institute
Brigham and Women’s Hospital
Assistant Professor of Medicine,
Harvard Medical School
Boston, MA

Disclosure: Grants/Research Support: Bayer, Sotio, Bristol-Myers Squibb, Merck, Takeda, Dendreon/Valeant, Janssen Pharmaceutical, Medivation/Astellas, Genentech, and Pfizer; Consultant: Genentech, Dendreon, Pfizer, Medivation/Astellas, Kew Group, and Theragene.

Thomas E. Hutson, DO, PharmD, FACP
Director, GU Oncology Program
Co-Chair, Urologic Cancer Research and Treatment Center
Texas Oncology
Charles A. Sammons Cancer Center
Baylor University Medical Center
Professor of Medicine
Texas A&M HSC College of Medicine
Dallas, TX

Disclosure: Grants/Research Support: Pfizer, Novartis, Exelixis, Eisai Co., Ltd, Bristol-Myers Squibb, and AVEO Oncology; Consultant: Pfizer, Exelixis, Eisai Co., Ltd, Bristol-Myers Squibb, and AVEO Oncology; Member of Speakers Bureau: Pfizer, Exelixis, Eisai Co., Ltd, and Bristol-Myers Squibb.

Thomas Powles, MBBS, MRCP, MD
Clinical Professor of Genitourinary Oncology (HCC)
Experimental Cancer Medicine Centre
Barts Cancer Institute
Barts and The London School of Medicine and Dentistry
London, UK

Disclosure: Grants/Research Support: Roche Holding AG, AstraZeneca, Merck, and Bristol-Myers Squibb; Consultant: Roche Holding AG, and AstraZeneca.

Nizar M. Tannir, MD, FACP
Professor and Deputy Chairman
Department of Genitourinary Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure: Grants/Research Support: Bristol-Myers Squibb, Exelixis, Epizyme, Novartis, and Miranti; Consultant: Bristol-Myers Squibb, Exelixis, Nektar, Novartis, Pfizer, Argos Therapeutics, Inc., and Calithera Biosciences.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its cme/ce activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a cme/ce activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This cme/ce activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this cme/ce activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

1 of 3
PER Pulse™ Recap


Community Practice Connections™: Show Me the Data: The Experts Weigh-In on Evidence to Support Strategies for Classic Clinical Scenarios in Renal Cell Carcinoma is a series of short content summaries and video interviews with the faculty of a live CME-certified symposium held in June 2017 in Chicago, Illinois. In this online activity, expert faculty discuss standards of care and emerging strategies for renal cell carcinoma (RCC). It features commentary on:

  • Frontline treatment for advanced RCC, by Daniel George, MD, and Toni Choueiri, MD
  • Second-line treatment selection for advanced RCC, by Thomas E. Hutson, DO, PharmD, and Toni Choueiri, MD
  • Treatment strategies for non-clear cell RCC, by Nizar M. Tannir, MD, and Toni Choueiri, MD
  • Adjuvant therapy for RCC, by Lauren C. Harshman, MD, and Toni Choueiri, MD
  • Using biomarkers to personalize care for patients with RCC, Thomas Powles, MBBS, MRCP, MD, and Toni Choueiri, MD

This first of 3 PER Pulse™ Recaps summarizing the online program focuses on Dr Hutson’s answers to questions about adjuvant targeted therapy for RCC, during which he discussed:

  • The approaches he would take throughout the case of a 64-year-old male with a history of metastatic RCC, who experienced mild toxicity, indolent growth, and eventual disease progression while on frontline sunitinib
  • The relevance of response to prior therapy when making decisions about next-line therapy
  • His perspective on RCC trial data presented in Chicago 2017

Key takeaways for community oncologists regarding therapeutic selection/sequencing beyond the first line of therapy

2 of 3
PER Pulse™ Recap


Community Practice Connections™: Show Me the Data: The Experts Weigh-In on Evidence to Support Strategies for Classic Clinical Scenarios in Renal Cell Carcinoma CME-certified symposium held in June 2017 in Chicago, Illinois. In this online activity, expert faculty discuss standards of care and emerging strategies for renal cell carcinoma (RCC). It features commentary on:

  • Frontline treatment for advanced RCC, by Daniel George, MD and Toni Choueiri, MD
  • Second-line treatment selection for advanced RCC, by Thomas E. Hutson, DO, PharmD, and Toni Choueiri, MD
  • Treatment strategies for non-clear cell RCC, by Nizar M. Tannir, MD, and Toni Choueiri, MD
  • Adjuvant therapy for RCC, by Lauren C. Harshman, MD, and Toni Choueiri, MD
  • Using biomarkers to personalize care for patients with RCC, Thomas Powles, MBBS, MRCP, MD, and Toni Choueiri, MD

This second of 3 PER Pulse™ Recaps summarizing the online program focuses on Dr Tannir’s answers to questions about management of non-clear cell RCC, during which he discussed:

  • His approach toward a patient with papillary type 2 RCC, Fuhrman grade 3 with extensive necrosis, lymphovascular invasion including perinephric adipose tissue, and 54 of 55 lymph nodes positive
  • His general, evidence-based treatment recommendations for patients with non-clear cell RCC
  • Key biological differences between non-clear cell RCC and clear cell RCC that drive their distinct treatment approaches
  • Recent practice-changing or potentially practice-changing trial data from studies of non-clear cell RCC
  • Select ongoing trials in this setting that have the potential to change practice in the future 

3 of 3
PER Pulse™ Recap


Community Practice Connections™: Show Me the Data: The Experts Weigh-In on Evidence to Support Strategies for Classic Clinical Scenarios in Renal Cell Carcinoma is a series of short content summaries and video interviews with the faculty of a live CME-certified symposium held in June 2017 in Chicago, Illinois. In this online activity, expert faculty discuss standards of care and emerging strategies for renal cell carcinoma (RCC). It features commentary on:

  • Frontline treatment for advanced RCC, by Daniel George, MD and Toni Choueiri, MD
  • Second-line treatment selection for advanced RCC, by Thomas E. Hutson, DO, PharmD, and Toni Choueiri, MD
  • Treatment strategies for non-clear cell RCC, by Nizar M. Tannir, MD, and Toni Choueiri, MD
  • Adjuvant therapy for RCC, by Lauren C. Harshman, MD, and Toni Choueiri, MD
  • Using biomarkers to personalize care for patients with RCC, Thomas Powles, MBBS, MRCP, MD, and Toni Choueiri, MD

This third of 3 PER Pulse™ Recaps summarizing the online program focuses on Dr Powles’ answers to questions about biomarkers and personalized care in RCC, during which he discussed:

  • His approach toward a 71-year-old female with metastatic disease with the primary tumor in situ (T3 G3 renal cancer), Memorial Sloan Kettering Cancer Center Score for Metastatic Rental Cell Carcinoma (MSKCC/Motzer) intermediate risk
  • The significance of prognostic risk status toward patient selection for nephrectomy
  • How he using biomarkers to guide the care of his own patients with RCC
  • Recent progress made in the area of biomarkers for RCC
  • Planned or ongoing studies of biomarkers in RCC that have the potential to change practice






Become a Member

Forgot Password?
Filter By